[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339727-105":3,"detail-sidebar-cat-0-en-105":73,"doc-detail-339727-en":122},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":66,"head_meta":68,"extra_data":70,"updated_unix":72},105,"en","dusp6-inhibition-overcomes-neuregulinher3-driven-therapy-tolerance-in-her2-breast-cancer","DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer","","Despite clinical benefits of tyrosine kinase inhibitors (TKIs), many tumors reactivate proliferation during continuous therapy. This study profiles HER2+ breast cancer cells transitioning from dormant drug-tolerant states to reproliferating cells under ongoing HER2 inhibitor treatment. Phosphatase DUSP6 is suppressed in dormant cells but strongly induced during regrowth. DUSP6 associates with poor patient survival, promotes apoptosis resistance, and its blockade prevents therapy tolerance. Mechanistically, DUSP6 supports HER3 expression via the neuregulin-HER3 axis, and targeting shows in vivo tumor control and synthetic lethal synergy with HER2 inhibitors.",{"@graph":14,"@context":65},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/dusp6-inhibition-overcomes-neuregulinher3-driven-therapy-tolerance-in-her2-breast-cancer/339727/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/dusp6-inhibition-overcomes-neuregulinher3-driven-therapy-tolerance-in-her2-breast-cancer/339727.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59],{"name":60,"@type":61,"acceptedAnswer":62},"What is the mechanistic link between DUSP6 and HER3-driven resistance?","Question",{"text":63,"@type":64},"DUSP6 positively regulates HER3 expression, and its impact on HER2 inhibitor tolerance is mediated through the neuregulin-HER3 signaling axis.","Answer","https://schema.org",{"og:url":32,"og:type":67,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":69,"canonical":32},"index,follow",{"doc_id":71,"site_id":7},339727,1790803897,{"code":4,"msg":74,"data":75},"success",[76,80,84,88,93,98,103,106,111,114,118],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":77,"show_sort_weight":78,"slug":79},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":81,"show_sort_weight":82,"slug":83},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Exam",70,"exam",{"id":89,"doc_module":4,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},5,"Comic",60,"comic",{"id":94,"doc_module":4,"doc_module_name":25,"category_name":95,"show_sort_weight":96,"slug":97},6,"Technology",50,"technology",{"id":99,"doc_module":4,"doc_module_name":25,"category_name":100,"show_sort_weight":101,"slug":102},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":104,"slug":105},30,"research-report",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},9,"Religion & Spirituality",20,"religion-spirituality",{"id":109,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":109,"slug":113},"World Cup","world-cup",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":115,"slug":117},10,"Lifestyle","lifestyle",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":89,"slug":121},19,"General","general",{"code":4,"msg":74,"data":123},{"doc_id":71,"user_id":124,"nickname":42,"user_avatar":125,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":131,"language":132,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":12,"update_tm":136,"read_time":137,"preview_page_count":33,"preview_urls":138},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \nDUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer  \nMajid Momeny1,2 ✉, Mari Tienhaara 3,4, Mukund Sharma 1,4, Deepankar Chakroborty3,4, Roosa Varjus1, Iina Takala 3,4, Joni Merisaari1, Artur Padzik1, Andreas Vogt 5, Ilkka Paatero 1, Klaus Elenius 3,4, Teemu D Laajala 6, Kari J Kurppa 3,4 & Jukka Westermarck 1,4 ✉  \nAbstract  \nDespite clinical beneﬁts of tyrosine kinase inhibitors (TKIs) in cancer, most tumors can reactivate proliferation under TKI therapy. Here we present transcriptional proﬁling of HER2+ breast cancer cells transitioning from dormant drug tolerant cells to reproliferating cells under continuous HER2 inhibitor (HER2i) therapy. Focusing on phosphatases, expression of dual-speciﬁcity phosphatase DUSP6 was found inhibited in dormant cells, but strongly induced upon regrowth. DUSP6 expression also selectively associated with poor patient survival in HER2+ breast cancers. DUSP6 overexpression conferred apoptosis resistance, whereas its pharmacological blockade prevented therapy tolerance development under HER2i therapy. DUSP6 targeting also synergized with clinically used HER2i combination therapies. Mechanistically DUSP6 is a positive regulator of HER3 expression, and its impact on HER2i tolerance was mediated by neuregulin-HER3 axis. In vivo, genetic targeting of DUSP6 reduced tumor growth in brain metastasis model, whereas its pharmacological targeting induced synthetic lethal therapeutic effect in combination with HER2i. Collectively this work demonstrates that DUSP6 drives escape from HER2i-induced dormancy, and that DUSP6 is a druggable target to overcome HER3-driven TKI resistance.  \nKeywords Non-genetic Drug Tolerance; Lapatinib; Neratinib; BCI; FOXM1 Subject Category Cancer  \n[https://doi.org/10.1038/s44321-024-00088-0](https://doi.org/10.1038/s44321-024-00088-0)  \nReceived 4 September 2023; Revised 8 May 2024; Accepted 24 May 2024  \nPublished online: 17 June 2024  \nIntroduction  \nTo develop therapeutic resistance, tumor cells undergo distinct evolutionary stages, starting with induction of dormancy and nongenetic drug tolerance, followed by epigenetic changes and ﬁnally resistance-conferring genetic mutations (De Conti et al, 2021; Hata et al, 2016; Marine et al, 2020) . These different phases were  \noriginally demonstrated for EGFR-targeted therapies in non-small cell lung cancer (NSCLC) cells (Sharma et al, 2010), but the concept has been expanded more recently to other malignancies including HER2+ breast cancer (Chang et al, 2022; De Conti et al, 2021; Dhimolea et al, 2021; Hata et al, 2016; Kurppa et al, 2020; Sharma et al, 2010) . Based on these studies, there is ample of omics data from dormant cells (also called as drug tolerant persisters; DTPs) from different cancer types treated with variety of therapies. However, our understanding of the molecular mechanisms behind the regrowth of DTPs under continuous therapy is still rudimentary. Especially, to our knowledge there are no published studies describing transcriptional landscapes of transition from DTP to drug tolerant expanding cells (DTEP), or transition of DTEP cells to long-term resistant (LR) cells upon TKI therapies.  \nThe human epidermal growth factor receptor 2 (HER2; encoded by ERBB2) is overexpressed in ~15–25% of human breast cancersand associates with a poor patient survival (Arteaga and Engelman, 2014; Haikala and Janne, 2021) . HER2 belongs to the ERBB family of receptor tyrosine kinase (RTK) with four members: HER1 (EGFR), HER2, HER3, and HER4 . Upon ligand binding, the ERBB receptors homo-and heterodimerize and activate downstream signaling pathways including PI3K/AKT and RAS/MAPK/ERK, which regulate cell proliferation, survival, and the metastatic dissemination (Arteaga and Engelman, 2014; Haikala and Janne, 2021) . Multiple HER2-targeted therapies, including the monoclonal antibody trastuzumab and small molecule tyrosine kinase inhibitors (TKIs) have been approved for the treatm","cbCainmpRlnzgqFK","https://ap.wps.com/l/cbCainmpRlnzgqFK","pdf",3751944,27,"English","# Abstract\n# Introduction","[{\"question\":\"What is the mechanistic link between DUSP6 and HER3-driven resistance?\",\"answer\":\"DUSP6 positively regulates HER3 expression, and its impact on HER2 inhibitor tolerance is mediated through the neuregulin-HER3 signaling axis.\"}]","DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer | PDF",1790031871,68,[139,143,147,151],{"page_no":22,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/307294f2c959aaf2ee8d5adcfc236ba2.webp",983,1305,{"page_no":26,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b895a44743ddaa2456db6ce0637abdf8.webp",982,1304,{"page_no":30,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb6a0e064ec83955242274b86fa0a557.webp",981,1303,{"page_no":33,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa440a870d58effac222b575c989c123.webp",980,1301]